Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 6/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548359 | 0.85 | NISCH (0.52) | NISCHPRMT1 | |
| SCHEMBL13204584 | 0.81 | NISCH (0.54) | NISCHPRMT1 | |
| SCHEMBL548343 | 0.78 | NISCH (0.50) | NISCHPRMT1 | |
| SCHEMBL8677423 | 0.78 | NISCH (0.50) | NISCHPRMT1 | |
| SCHEMBL549218 | 0.78 | TOP2A (0.56) | NISCHPRMT1PRMT3EHMT2PRMT6 | |
| SCHEMBL14599548 | 0.77 | PRMT1 (0.49) | NISCHPRMT1 | |
| SCHEMBL14599545 | 0.76 | NISCH (0.48) | NISCHPRMT1 | |
| SCHEMBL8477890 | 0.75 | NPC1 (0.58) | NISCHPRMT1 | |
| SCHEMBL8477719 | 0.74 | NISCH (0.55) | NISCHPRMT1PRMT3EHMT2PRMT6 | |
| SCHEMBL23775778 | 0.74 | PRMT1 (0.44) | NISCHPRMT1PRMT3EHMT2PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | claimed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | claimed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | claimed |
| US-20190145981-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | SPHINGOTEC THERAPEUTICS GMBH (DE) | 2019-05-16 | — | — | US | disclosed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| CN-102083429-B | Ido inhibitors | NEWLINK GENETICS | 2014-05-28 | — | — | CN | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | disclosed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | NISCH 1863/4885PRMT1 19/4885F2 3828/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | NISCH 1863/4885PRMT1 19/4885F2 3828/4885 |
| US-20190145981-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | DPP3, DPP4, DPP7 | NISCH 2601/4885PRMT1 3595/4885F2 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.